GlassScriptPhysician profile
Jacklyn M Gideon
NPI 1629515572
$38,179.69
in general payments reported to CMS, 2019-2025
14 companies · $4,988 in 2025
The $4,988 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,627 · 2022: $15K · 2023: $7,934 · 2024: $6,807 · 2025: $4,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $4,470 · Consulting Fee: $3,713 · Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,024.50 |
| Travel and Lodging | $4,470.32 |
| Consulting Fee | $3,712.50 |
| Food and Beverage | $1,520.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,097.99 | 2023-2025 | |
| Janssen Biotech, INC. | $8,160.37 | 2021-2024 | Imbruvica |
| Pharmacyclics LLC, An Abbvie Company | $6,567.63 | 2022-2023 | Imbruvica |
| Genzyme Corporation | $5,434.95 | 2021-2023 | |
| Genmab U.S., INC. | $2,663.35 | 2023-2024 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $2,240.19 | 2022 | |
| Celgene Corporation | $2,159.74 | 2021-2023 | Pomalyst |
| Beone Medicines USA, INC. | $900.00 | 2025 | Brukinsa |
| Incyte Corporation | $365.00 | 2021 | |
| Beigene USA, INC. | $157.14 | 2024 | Brukinsa |
| Tg Therapeutics, INC. | $148.59 | 2021 | |
| Invivyd INC | $128.32 | 2025 | Pemgarda |
| Jazz Pharmaceuticals INC. | $121.14 | 2025 | |
| Adc Therapeutics America, INC. | $35.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacklyn Gideon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.